Companies › Upstream Bio
1 active drug program in 2 registered trials: 2 Phase 2; Respiratory; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Verekitug (UPB-101) | – | Phase 2 | Severe Asthma; Chronic Obstructive Pulmonary Disease | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06966479 | Verekitug (UPB-101) | Phase 2 | Severe Asthma | Respiratory | Sep 2027 |
| NCT06981078 | Verekitug (UPB-101) | Phase 2 | Chronic Obstructive Pulmonary Disease | Respiratory | Oct 2027 |
Cash and short-term investments of $207m on 2026-09-30; operating cash outflow about $185m a year; runway about 14 months at that burn, to Nov 2027; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Connect Biopharm Aqualung Therapeutics PPD Development, LP Rein Therapeutics Shanghai Mabgeek Biotech.Co.Ltd
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.